Testing chemotherapy choices for early breast cancer after surgery
Part of Cancer, Skin clinical trials.
This Phase 1 study tests different chemotherapy approaches in people with breast cancer that has been surgically removed but is early stage. It aims to find a chemotherapy plan that’s safe and works well right after surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older
- Your breast cancer was confirmed as infiltrating ductal carcinoma (by biopsy/pathology)
- You must have generally healthy “major organs” and not severe problems with liver, heart, or other key organs
- Your blood counts must be strong enough (white blood cells and neutrophils, platelets, and hemoglobin) and you should not need transfusions
- You must be in an early stage (at least stage IA) and not have distant metastasis
- You need to be able to sign informed consent and have a good energy level (WHO performance status 0 or 1)
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial is comparing two types of chemotherapy (standard taxane vs a newer albumin-bound paclitaxel) given after surgery to see which is better at preventing breast cancer from returning. It is for women with HER2-negative breast cancer that has a high risk of coming back.
This trial tests a chemotherapy combination (CMC) for people with early-stage, hormone receptor-positive, HER2-negative breast cancer who have a high risk of recurrence. It aims to understand if this oral regimen is effective and tolerable.
This trial tests giving chemotherapy before surgery to shrink breast tumors, which may make surgery easier or allow breast-conserving options. It is for adults with invasive breast cancer that has not spread to distant organs.
This study tests whether some patients with early-stage, hormone-positive breast cancer can safely skip chemotherapy and just use hormone therapy plus a CDK4/6 inhibitor pill after surgery. If you qualify, you may avoid chemo side effects while still reducing the chance of the cancer coming back.
This trial tests whether adding the antibiotic doxycycline to standard chemotherapy before surgery can better target breast cancer stem cells in people with ER-positive, HER2-negative breast cancer. The goal is to improve treatment response.
This trial tests whether giving chemotherapy before surgery, guided by the genetic profile of your tumor, can improve outcomes for a specific type of HER2-positive breast cancer. It aims to tailor treatment to each person's cancer biology.
Hear when a new Breast cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.